TIAM2
ENSC icon

Tru Independence Asset Management 2’s Ensysce Biosciences ENSC Stock Holding History

Tru Independence Asset Management 2’s Portfolio ENSC Stock Details ENSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.77K Hold
13,000
– – ﹤0.01% 97
2026
Q1 		$7K Buy
13,000
+1,000
+8% +$634 ﹤0.01% 82
2025
Q4 		$11K Buy
12,000
+1,500
+14% +$2.78K 0.01% 86
2025
Q3 		$24.9K Buy
+10,500
New +$22.6K 0.02% 86

Other funds holding ENSC

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Tru Independence Asset Management 2's ENSC Position: Q2 2026 in Review

Tru Independence Asset Management 2 held its Ensysce Biosciences (ENSC) position steady in Q2 2026 at 13,000 shares worth $3.77K. The position accounts for ﹤0.01% of the portfolio, ranked #97.

Tru Independence Asset Management 2 first reported a position in ENSC in Q3 2025 and has held it in 4 quarters since. The position peaked at $24.9K in Q3 2025. 18 funds tracked by Wall St. Rank hold ENSC as of Q2 2026.

  • Tru Independence Asset Management 2 held 13,000 shares of Ensysce Biosciences worth $3.77K as of Q2 2026.
  • Tru Independence Asset Management 2 left its Ensysce Biosciences share count unchanged in Q2 2026.
  • Ensysce Biosciences made up ﹤0.01% of Tru Independence Asset Management 2's portfolio in Q2 2026, its #97 holding.
  • Tru Independence Asset Management 2 first reported a position in Ensysce Biosciences in Q3 2025 and has held it in 4 quarters since.
  • Tru Independence Asset Management 2's Ensysce Biosciences position peaked at $24.9K in Q3 2025.
  • 18 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q2 2026.

Based on Tru Independence Asset Management 2's 13F filing for Q2 2026, filed 11 Aug 2026.